May 14, 2026

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.

Conexiant

May 14, 2026

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Conexiant

May 12, 2026

Digitalis Reduces HF Events but Not Mortality

Meta-analysis of randomized trials found fewer worsening heart failure events among patients with reduced or mildly reduced ejection fraction

Conexiant

April 17, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Conexiant

April 03, 2026

Acoramidis Linked to Lower Mortality Through 54 Months

Early treatment was associated with sustained reductions in mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy

Conexiant

April 01, 2026

Tirzepatide Linked to Lower Cardiorenal Events

Researchers evaluate expanded six-component outcome in high-risk patients with diabetes

Conexiant

April 01, 2026

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Conexiant

March 31, 2026

Sudden Death Trajectories in HFpEF, HFmrEF

Clinical changes before death overlap across outcomes

Conexiant

March 30, 2026

Risk Model Stratifies Heart Failure Outcomes

Biomarker score estimates risk and absolute benefit of finerenone across patient groups

Conexiant

March 30, 2026

Neurofilament Levels Linked to AF Risk

Higher levels associated with stroke, death, and heart failure in long-term cohort

Conexiant